Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Temporal and Clonal Resolution of Cellular Evolution Under Stress

ABSTRACT: Dissecting cellular evolution under transient versus persistent stress is essential for understanding both healthy and pathological processes. Yet cellular stress responses involve nonlinear dynamics and survival bottlenecks, making them challenging to study. We develop a framework that combines single-cell multiomic lineage tracing with statistical modeling to quantify how individual cells contribute to the future population, by explicitly modeling exponential expansion and intra-clonal heterogeneity. Applied to a cancer model under short- and long-term treatment, we identify clones primed to endure treatment versus ones that survive by producing diverse progeny, enabling characterization of molecular features enriched in each clonal survival strategy. This framework can quantify treatment-driven selection and adaptation, revealing that their relative contributions to population dynamics vary between treatments. Furthermore, short- and long-term treatment results in expansion of distinct clones characterized by different gene programs and transcription factor activity. Notably, certain pathways such as AP-1 signaling can limit initial cancer cell growth but promote later resistance, and such opposing associations are consistently observed in independent experiments and clinical data. Together, this study introduces a generalizable approach for investigating cellular evolution in a time- and clone-resolved manner, and highlights time-dependent molecular programs that underlie stress responses.

ORGANISM(S): Homo sapiens

PROVIDER: GSE305751 | GEO | 2026/08/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Modeling clonal evolution and oncogenic dependency in vivo in the context of hematopoietic transformation

Project description:Cancer evolution is a multifaceted process involving the acquisition of somatic mutations and progressive epigenetic dysregulation of cellular fate. Both cell-intrinsic mechanisms and environmental interactions provide selective pressures capable of promoting clonal evolution and expansion, with single-cell and bulk DNA sequencing offering increased resolution into this process. Advances in genome editing, single-cell biology and expressed lentiviral barcoding have enabled new insights into how transcriptional/epigenetic states change with clonal evolution. Despite the extensive catalog of genomic alterations revealed by resequencing studies, there remain limited means to functionally model and perturb this evolutionary process in experimental systems. Here we integrated multi-recombinase (Cre, Flp, and Dre) tools for modeling reversible, sequential mutagenesis from premalignant clonal hematopoiesis to acute myeloid leukemia. We demonstrate that somatic acquisition of Flt3 activating mutations elicits distinct phases of acute and chronic activation resulting in differential cooperativity with Npm1 and Dnmt3a disease alleles. We next developed a generalizable allelic framework allowing for the reversible expression of oncogenic mutations at their endogenous loci. We found that reversal of mutant Flt3 resulted in rapid leukemic regression with distinct alterations in cellular compartments depending upon co-occurring mutations. These studies provide a path to model sequential mutagenesis and deterministically investigate mechanisms of transformation and oncogenic dependency in the context of clonal evolution.

2022-05-25 | GSE203454 | GEO

Modeling clonal evolution in Fanconi anemia

Project description:Modeling clonal evolution in Fanconi anemia

| PRJNA847938 | ENA

Cell of origin epigenetic priming determines susceptibility to Tet2 mutation

Project description:Hematopoietic stem cell (HSC) mutations can result in clonal hematopoiesis (CH) with heterogeneous clinical outcomes. Here, we investigated how the cell state preceding Tet2 mutation impacts the pre-malignant phenotype. Using an inducible system for clonal analysis of myeloid progenitors, we found that the epigenetic features of clones at similar differentiation status were highly heterogeneous and functionally responded differently to Tet2 mutation. Cell differentiation stage also influenced Tet2 mutation response indicating that the cell of origin's epigenome modulates clone-specific behaviors in CH. Molecular features associated with higher risk outcomes include Sox4 that sensitized cells to Tet2 inactivation, inducing dedifferentiation, altered metabolism and increasing the in vivo clonal output of mutant cells, as confirmed in primary GMP and HSC models. Our findings validate the hypothesis that epigenetic features can predispose specific clones for dominance, explaining why identical genetic mutations can result in different phenotypes.

2024-04-30 | MTBLS9914 | MetaboLights

Kinome profiling of venetoclax-resistant wild type and NRAS-G12C MOLM-14 cells

Project description:Despite efficacy of FLT3 and BCL2 inhibition in acute myeloid leukemia (AML), relapse limits survival. Mutation status and AML monocytic differentiation are implicated in resistance. On-treatment tumor evolution may select for genetically distinct clones or shifts in differentiation not resolvable by bulk sequencing. We performed multiomic single cell (SC) DNA/protein and RNA/protein profiling of patients treated on a clinical trial of the BCL2 inhibitor venetoclax and the FLT3 inhibitor gilteritinib (Ven/Git) to characterize immunophenotypic, transcriptional, and genetic clonal evolution on therapy. We found that while Ven/Gilt effectively eliminated FLT3 mutant clones, it selected for RAS mutations, RAS pathway activation and RAS-associated monocytic differentiation. In an in vitro model of monocytic differentiation associated with heightened RAS pathway activation, we demonstrated that MEK inhibition re-sensitized to Ven/Gilt. Kinome profiling of Molm14 cells, both NRAS WT and NRAS G12C, both treatment-naive and venetoclax resistant, additionally shows RAS upregulation with venetoclax resistance. These data indicate RAS signaling is central to FLT3 and BCL2 inhibitor resistance, is tightly coupled to monocytic differentiation and can be overcome by RAS pathway inhibition.

2026-06-15 | PXD068585 | Pride

Heterogeneity in hematopoietic stem cell enables adaptation to the aged microenvironment

Project description:Aging reshapes hematopoietic stem cell (HSC) behavior, yet how pre-existing heterogeneity forecasts clonal performance in aged microenvironments remains unclear. Using cellular barcoding and single cell-RNA-seq to longitudinally sample shared sister-clones across hetero- and homochronic transplants in mice, we quantify (i) intra- and inter-cellular transcriptional heterogeneity in young and old HSC, (ii) differential self-renewal and clonal fitness of HSC in reconstituted hematopoiesis, and (iii) clone-wise associations between pre-existing programs and fitness in aging contexts via predictive machine learning models. Old HSC exhibit greater heterogeneity and rates of generation of heterogeneity, driven by specific gene sets with known roles in HSC fitness. Old HSC exhibit higher self-renewal in old relative to young hosts, likely reflecting adaptation over life to the aged altered niche. Clones with higher fitness in aged mice are enriched for signatures of quiescence, genome integrity/DNA repair, and inflammaging when compared to lower-fitness clones before transplantation. Pre-existing heterogeneity predicts both higher clone fitness and higher self-renewal in the old hosts after transplantation, providing greater phenotypic variability for selection of adaptive clones. Together, these data argue that intrinsic aging encodes variable clonal ‘starting positions’ that interact with niche age to shape hematopoietic output. Our results contextualize recent clonal tracing studies in native hematopoiesis and aging—where lineage output is clonally restricted and age-expanded clones persist—and extend them by prospectively linking baseline HSC state variation to subsequent fitness under aged conditions. These findings nominate actionable, pre-transplant molecular predictors of clonal performance and suggest strategies to modulate aging programs to rebalance hematopoiesis.

2026-07-21 | GSE325995 | GEO

Heterogeneity in hematopoietic stem cell enables adaptation to the aged microenvironment [celltag_cross_exp4]

2026-07-21 | GSE326529 | GEO

Heterogeneity in hematopoietic stem cell enables adaptation to the aged microenvironment [scRNA-seq]

2026-07-21 | GSE327449 | GEO

The clonal basis of either resistance or response to ivosidenib and venetoclax ± azacitidine is established early in IDH1-mutated myeloid malignancies

Project description:A recent phase Ib/II trial of ivosidenib and venetoclax ± azacitidine in patients with IDH1-mutated myeloid malignancies showed a promising 94% response rate. However, relapse was still common. To define the clonal and cellular basis of acquired resistance and sustained response, we performed single-cell studies on longitudinal samples from 8 patients. Whilst all 8 patients initially responded to treatment, 6 relapsed and 2 remained in sustained remission for > 4 years. Therapy-resistant clones were selected early, within 3 treatment cycles, preceding relapse by months or years. Treatment failure was associated with either emerging genetically evolved clones or acquired differentiation arrest of pre-existing clones; in both cases, within small immunophenotypic leukemic stem cell (LSC) populations. In sustained response, all leukemic clones were eradicated and rapidly replaced by clonal and wild type hematopoiesis. If validated in larger cohorts, early clonal assessment of LSCs may be predictive of long-term outcome, providing a clinically relevant endpoint.

2025-07-24 | GSE273135 | GEO

Oligo-CALL: A Next-Generation Barcoding Platform for Studying Resistance to Targeted Therapy [bulk RNA-seq]

Project description:Deconvolving heterogeneous cell populations and tracing individual clonal trajectories are essential for unraveling complex biological processes, such as therapy resistance. Although CRISPR-assisted cellular barcoding holds promises for lineage tracing, current platforms exhibit limitations underscored by suboptimal efficiencies and incompatibilities with single-cell transcriptomics. We introduce Oligo-CALL (Oligonucleotide-induced CRISPRa-Assisted Lineage Labeling), a new cellular barcoding system enabling precise tumor clone tracking, convenient live-clone isolation without additional genomic modification, and compatibility with single-cell RNA sequencing. Applying Oligo-CALL to human lung cancer cells revealed key insights into the resistance to KRAS G12C inhibitors (G12Ci). Clonal fate assays demonstrated that certain clones were repeatedly enriched under G12Ci pressure, indicating a “predestined” rather than “stochastic” mode of resistance. Paired functional assays of treatment-naïve versus resistant clones revealed clone-specific, acquired resistance phenotypes, manifesting as transient or permanent. Single-cell transcriptomics confirmed the activation of diverse yet clone-specific adaptive pathways underlying G12Ci resistance. Together, Oligo-CALL offers a powerful way to investigate the evolution of resistance to targeted therapies.

2025-10-06 | GSE299096 | GEO

Oligo-CALL: A Next-Generation Barcoding Platform for Studying Resistance to Targeted Therapy [scRNA-seq]

2025-10-06 | GSE299095 | GEO